Drug Information

Drug General Information
Drug ID
D0R0TS
Former ID
DNCL002998
Drug Name
MK-1439
Drug Type
Small molecular drug
Indication Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] Phase 3 [525133]
Company
Merck
Formula
C17H11ClF3N5O3
Canonical SMILES
CN1C(=NNC1=O)CN2C=CC(=C(C2=O)OC3=CC(=CC(=C3)C#N)Cl)C(F)<br />(F)F
InChI
1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)
InChIKey
ZIAOVIPSKUPPQW-UHFFFAOYSA-N
PubChem Compound ID
58460047
PubChem Substance ID
138785402, 162109074, 163370732, 163662251, 164147214, 172132099, 198985579, 224534916, 228614684
Target and Pathway
Target(s) HIV reverse transcriptase Target Info Inhibitor [532619]
References
Ref 525133ClinicalTrials.gov (NCT02403674) Comparison of MK-1439A and ATRIPLA in Treatment-Naive Human Immunodeficiency Virus (HIV)-Infected Participants (MK-1439A-021). U.S. National Institutes of Health.
Ref 532619Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett. 2014 Feb 1;24(3):917-22.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.